U.S. company's new corona vaccine clinical trial “antibody levels rise” 6:19, May 19
An American pharmaceutical company, which is developing a vaccine for a new type of coronavirus, "demonstrated the possibility of prevention" on the 18th, saying that the early results of the clinical trial showed that the antibody level of the inoculated person increased. Announced.
The American pharmaceutical company "Moderna" has been conducting clinical trials of the new coronavirus vaccine since March this year in collaboration with NIH = National Institute of Health.
Moderna announced on the 18th that the level of antibodies to the new coronavirus in the blood increased among vaccinated people as an early result of the first stage clinical trial to confirm the function and safety of the vaccine. Did.
According to the announcement, the level of specific antibodies that prevent virus infection in people 43 days after the first vaccination rose to the same level as those who recovered after infection or more. Our vaccine has demonstrated the potential for prevention. "
The first stage clinical trials target 45 people aged 18 to 55 years old, but the results of the specific antibody announced this time were limited to 8 people, and the publication of the results of the entire clinical trial is awaited. I am.
In addition, it has not been sufficiently demonstrated in humans that infection with the new coronavirus can be prevented even if the antibody level rises, and some of the vaccinated persons have symptoms such as fever and headache. Therefore, confirmation of actual effects and safety is a future issue.
Moderna has already received approval to proceed to the second stage clinical trial that verifies the amount of vaccine to be inoculated, and in July it is expected to finally proceed to the third stage to confirm the effect and safety. I am.